The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Barclays Lifts FTSE's Lenders

Fri, 23rd Oct 2020 10:46

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.

----------

FTSE 100 - WINNERS

----------

Barclays up 6.2%. The lender kicked off the UK banking reporting season with a "resilient" performance in the third quarter of 2020. Barclays said pretax profit for the three months ended September came in at GBP1.15 billion, up sharply from GBP246 million a year earlier. Third-quarter group income declined 6% to GBP5.20 billion from GBP5.54 billion, however. Other FTSE 100 lenders rose in a positive read-across. StanChart climbed 4.7%, Lloyds was up 4.4%, HSBC rose 3.8% and NatWest was up 3.3%. They all report third-quarter results next week.

----------

FTSE 250 - LOSERS

----------

Airtel Africa down 4.5%. The Africa-focused mobile operator halved its interim dividend to 1.5 US cents from 3 cents a year earlier. Revenue in the first half of 2020 increased by 11% to USD1.82 billion from USD1.65 billion a year ago, with second-quarter revenue growth of 14%. Reported operating profit for the half year was USD472 million, up 20% year-on-year.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Pendragon, up 21%. The motor retailer is piling on more gains after surging 23% on Thursday. It had said Thursday that underlying pretax profit for the three months to ended September was GBP27.3 million, up sharply from GBP3.0 million from a year earlier.

----------

Goco Group up 6.3%. The price comparison site said revenue in the nine months ended September is up 13% annually at GBP130.5 million. Customers at its AutoSave Live arm have more than doubled to 597 from 241 a year earlier.

----------

Evgen Pharma, up 16%. The clinical stage drug development firm has landed all regulatory approvals for the STAR trial of its SFX-01 treatment. The drug is used to treat acute respiratory infections. Recruitment for the trial will begin at the end of October.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

Avingtrans PLC, down 7.4%. Shareholder Nigel Wray sold 3.2 million shares in the company at 250 pence each, landing GBP8.1 million. Wray no longer has a stake in the company, which provides systems and services to the energy and industrial sectors.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
20 Sep 2021 14:50

IN BRIEF: Evgen Pharma's SFX-01 effective on tumour cells

IN BRIEF: Evgen Pharma's SFX-01 effective on tumour cells

Read more
2 Sep 2021 11:56

IN BRIEF: Evgen SFX-01 granted orphan drug designation by US FDA

IN BRIEF: Evgen SFX-01 granted orphan drug designation by US FDA

Read more
13 Jul 2021 15:36

Evgen pleased with preclinical data on SFX-01

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced preclinical data demonstrating that 'SFX-01' was effective in in-vitro models of certain blood cancers on Tuesday.

Read more
13 Jul 2021 14:09

IN BRIEF: Evgen Pharma files brain tumour treatment request with FDA

IN BRIEF: Evgen Pharma files brain tumour treatment request with FDA

Read more
13 Jul 2021 11:25

IN BRIEF: Evgen Pharma encouraged by early data for SFX-01

IN BRIEF: Evgen Pharma encouraged by early data for SFX-01

Read more
13 Jul 2021 11:20

AIM WINNERS & LOSERS: Star Phoenix wins new deal; Ebiquity revenue up

AIM WINNERS & LOSERS: Star Phoenix wins new deal; Ebiquity revenue up

Read more
9 Jul 2021 11:51

Evgen Pharma halts trial as SFX-01 drug fails to help Covid patients

Evgen Pharma halts trial as SFX-01 drug fails to help Covid patients

Read more
9 Jul 2021 10:52

AIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle

AIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle

Read more
9 Jul 2021 10:33

Evgen 'surprised and disappointed' by findings in SFX-01 trial

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced the results of the interim safety and futility assessment readout of the first 100 patients treated in the 'STAR' Covid-19 trial of its lead asset, 'SFX-01', on Friday.

Read more
6 Jul 2021 16:10

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
15 Jun 2021 14:42

TRADING UPDATES: GB Group rebuilds dividend; IPF ups 2021 profit view

TRADING UPDATES: GB Group rebuilds dividend; IPF ups 2021 profit view

Read more
14 Jun 2021 13:19

TRADING UPDATES: Synectics loss narrows; Active Energy loss widens

TRADING UPDATES: Synectics loss narrows; Active Energy loss widens

Read more
14 Jun 2021 11:00

Evgen upbeat on new data on potential breast cancer treatment

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced new preclinical data on Monday, which showed 'SFX-01' could be of benefit to metastatic breast cancer (mBC) patients who had become resistant to CDK4/6 inhibitors.

Read more
26 Apr 2021 13:02

IN BRIEF: Evgen Pharma appoints Huw Jones as chief medical officer

IN BRIEF: Evgen Pharma appoints Huw Jones as chief medical officer

Read more
7 Apr 2021 16:22

IN BRIEF: Evgen Pharma notes publication on sulforaphane in Covid-19

IN BRIEF: Evgen Pharma notes publication on sulforaphane in Covid-19

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.